Related Experiment Video
Updated: Jul 13, 2026

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
Published on: May 29, 2020
[Autoimmune hepatitis in pediatric patients]
R García Romero1, J Martín de Carpi, C Bernal Cuartas
1Sección de Gastroenterología, Hepatología y Nutrición Pediátrica, Hospital Sant Joan de Déu, Barcelona. ruthgarciaromero@yahoo.es
Insights
Autoimmune hepatitis (AIH) in children presents variably and requires prompt diagnosis. Treatment with azathioprine and corticosteroids is effective, but relapses are common after steroid withdrawal, necessitating long-term management.
Area of Science:
- Pediatric Gastroenterology
- Hepatology
- Immunology
Context:
- Autoimmune hepatitis (AIH) is a progressive liver disease of unknown etiology.
- AIH can lead to liver necrosis and cirrhosis if left untreated.
- Understanding AIH in pediatric populations is crucial for timely diagnosis and management.
Purpose:
- To characterize autoimmune hepatitis in pediatric patients.
- To analyze clinical presentation, serological markers, and treatment outcomes in children with AIH.
Summary:
- A retrospective study identified seven pediatric AIH cases over 10 years, with a female predominance (71.5%).
- Patients presented with Type I (5/7) or Type II (2/7) markers, with ages ranging from 21 months to 12 years.
- Elevated aminotransferases (71.5%) and immunoglobulins (85%) were common; treatment with azathioprine and prednisone led to remission in 14 months, though relapses occurred in two patients after steroid withdrawal.
Impact:
- AIH diagnosis in children should consider presentations mimicking viral hepatitis.
- Concomitant elevation of aminotransferases and immunoglobulins warrants AIH investigation.
- Long-term management strategies are essential due to high relapse rates after corticosteroid withdrawal.
Background:
Autoimmune hepatitis (AIH) is an inflammatory disease of unknown origin that is responsible for progressive liver necrosis and ultimately cirrhosis.
Objective:
Our aim was to evaluate the characteristics of autoimmune hepatitis presenting in the pediatric age.
Material And Methods:
We conducted a retrospective study of all patients diagnosed with AIH in our hospital department during the last 10 years. Variables analyzed included age, sex, clinical presentation, hepatic function, immunoglobulins, autoimmunity markers, histology, treatment, need for transplant, and clinical evolution. According to the positive level of auto-antibodies, AIH patients were classified as type I AIH (ANA and/or smooth-muscle antibodies) and type II (anti-LKM-1).
Results:
Seven patients were diagnosed in this period -5 girls (71.5%) and 2 boys (28.5%). Five patients presented with type-I serological markers, and two with type-II markers. Age range at diagnosis was from 21 months to 12 years. In the type-I group, 3 patients presented with acute hepatitis while 2 other patients were diagnosed from laboratory findings while asymptomatic. Elevated aminotransferase (10 times the normal level) was observed in 71.5%, and 85% had elevated immunoglobulins. Treatment with azathioprine and prednisone was started after diagnosis with an average time to remission of 14 months. Two patients relapsed following steroid withdrawal.
Conclusion:
AIH can have different forms of clinical presentation, and is sometimes indistinguishable from viral hepatitis. AIH must be ruled out in patients presenting with concomitant elevation of aminotransferases and immunoglobulins. The commonly accepted treatment is a combination of azathioprine and corticosteroids. A high percentage of patients experience a relapse of disease after steroids are withdrawn. Therefore, some patients will need to stay on combined therapy with minimal doses of steroids.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Hepatitis
Viral Hepatitis I: Introduction
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
Pharmacokinetics in Pediatric Patients: Drug Excretion
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
